The packet does not certify diagnostic methods for keratoconus. Several ClinicalTrials.gov records study diagnostic or measurement approaches, including a hand-held corneal topographer, Brillouin microscopy for corneal ectasia, and corneal elastography with patient-specific modeling; these are research records rather than established diagnostic methods.

The packet's FDA-related records list Photrexa Viscous (riboflavin ophthalmic solution with ultraviolet A, sponsored by Glaukos Corporation) with APPROVED status for the treatment of keratoconus. A separate orphan designation is listed for copper sulfate (Glaukos Corporation) for the same indication; its status is DESIGNATED, and an orphan designation is not an approval. Other management approaches are not certified in this packet.

Prognosis is not certified in this packet.

ClinicalTrials.gov records in the packet include multiple active studies on keratoconus. Several concern corneal cross-linking, including a Phase 4 study of same-day bilateral epithelium-on cross-linking (NCT07629557, recruiting), a Phase 2 study of cross-linking for progressive keratoconus or corneal ectasia (NCT07841470, recruiting), and a Phase 3 randomized trial of collagen crosslinking (NCT01604135, active, not recruiting). Other records address a novel optical aperture contact lens, corneal lenticule implantation, and the measurement of intraocular pressure after cross-linking. Intervention types include medical devices, drug therapy, procedural interventions, and other interventions. In the packet's classified literature, epidemiology and natural history is the most common publication type.